Journal of Experimental Medicine
Journal of Experimental Medicine is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Journal of Experimental Medicine.
Journal of Experimental Medicine is a company.
Key people at Journal of Experimental Medicine.
Journal of Experimental Medicine (JEM) is not a company but a prestigious scientific journal that publishes original research providing novel conceptual insights into medical biology, particularly in immunology, cancer biology, vascular biology, microbial pathogenesis, neuroscience, and stem cell biology[1][2]. It serves the global scientific community by disseminating high-quality, peer-reviewed studies that advance understanding of disease pathogenesis and novel therapeutic approaches.
JEM is an academic journal focused on publishing cutting-edge research in experimental medicine and related biomedical fields. It serves researchers, clinicians, and academics by providing a platform for original findings that deepen knowledge of disease mechanisms and potential treatments. The journal emphasizes interdisciplinary studies and encourages submissions of human studies to bridge basic science and clinical applications[1]. It is widely respected for its rigorous editorial process and contribution to the medical biology literature.
Founded in 1896 at the Johns Hopkins School of Medicine by William Welch, a prominent figure in American medicine and the first president of the Rockefeller Institute's Board of Scientific Directors, JEM was created to publish enduring and outstanding studies in medical biology[2]. Welch initially edited the journal alone but later passed editorial responsibilities to others as the workload increased. Since 1905, the Rockefeller Institute has published the journal, which has maintained a tradition of accepting submissions from both internal and external laboratories, fostering a broad scientific dialogue[2].
JEM rides the ongoing trend of integrating molecular and cellular biology advances with clinical research to accelerate translational medicine. The timing is critical as biomedical research increasingly focuses on precision medicine, immunotherapies, and understanding complex disease mechanisms at a systems level. By providing a platform for interdisciplinary and human-focused studies, JEM influences the broader biomedical ecosystem by shaping research priorities and fostering collaboration between basic scientists and clinicians[1][2]. Its role supports innovation in therapeutic development and disease understanding, which are central to current healthcare challenges.
Looking ahead, JEM is poised to continue its leadership in publishing transformative research that bridges basic and clinical sciences. Trends such as single-cell technologies, immuno-oncology, and neuroimmunology will likely feature prominently in its future issues. The journal’s influence will evolve as it adapts to open-access models and digital dissemination, increasing accessibility and impact. Maintaining its rigorous editorial standards and embracing emerging biomedical fields will ensure JEM remains a cornerstone in experimental medicine publishing.
In summary, the Journal of Experimental Medicine is a venerable and influential scientific journal dedicated to advancing medical biology through high-quality research publication, rather than a company. Its rich history, broad scope, and editorial excellence distinguish it as a key player in the biomedical research landscape[1][2].
Key people at Journal of Experimental Medicine.
